Sponsor
DMCA
Novo Nordisk launches Wegovy in India, targets obesity treatment market, offers semaglutide-based weekly injection
Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 and Rs 26,050 per month, the injectable drug targets India's large obese population. The company aims to create awareness and collaborate with stakeholders to combat obesity, citing its significant impact on India's GDP.
English
नेपाली
हिन्दी
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Portuguese (Brazil)
Greek
Arabic
French
অসমীয়া
বাংলা